HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Meckling, S. Articles by Hagen, N. A. Search for Related Content PubMed PubMed Citation Articles by Meckling, S. Articles by Hagen, N. A.

Malignant supratentorial glioma in the elderly

Is radiotherapy useful?

From the Department of Clinical Neurosciences (Drs. Meckling, Forsyth, and Hagen), Foothills Hospital and University of Calgary; Department of Clinical Neurosciences (Neurosurgery) (Dr. Dold), Calgary General Hospital; Division of Epidemiology (Dr. Brasher), Prevention & Screening, Tom Baker Cancer Center and Department of Community Health Sciences, University of Calgary; and Brain Tumor Group, Department of Medicine (Drs. Forsyth and Hagen), Tom Baker Cancer Center, Calgary, Alberta, Canada.
Received September 15, 1995. Accepted in final form April 1, 1996.
Address correspondence reprint requests to Dr. N. Hagen, Department of Medicine, Tom Baker Cancer Center, 1331 29 St, Calgary, Alberta, Canada T2N 4N2.

Objectives: To determine (1) if radiotherapy (RT) improves survival or neurologic function in elderly patients with malignant supratentorial glioma (MSG) and (2) which prognostic factors predict survival. Background: The prevalence of MSG is increasing because both the number of elderly patients and the age-adjusted incidence are increasing. Because age is a powerful negative prognostic factor in MSG, it is not clear if RT is useful in the elderly. Design/Methods: We retrospectively studied 103 patients from the Southern Alberta Cancer Registry diagnosed January 1, 1978, to December 31, 1993, aged 70 yrs, with MSG in whom sufficient clinical and follow-up information was available. Multiple treatment and patient factors were compared with survival and neurologic function score. Diagnosis was confirmed in 15 (14.6%) by biopsy, in 66 (64.1%) by resection, and in 22 (21.4%) by clinical course and typical radiographic appearance only. Results: All patients died and median survival was 3.9 months. Better neurologic function at diagnosis and administration of RT were independently associated with significantly longer survivals (p = 0.001 and <0.001; log rank test). However, RT was only associated with longer survival in patients aged less than 80 years. Neurologic status only rarely improved following RT. Conclusions: The prognosis for elderly patients with MSG is poor. RT is unlikely to benefit patients who are aged 80 years or older. RT has a short-lived benefit for patients who are functionally disabled.

NEUROLOGY 1996;47: 901-905

This article has been cited by other articles:

				W. Roa, P.M.A. Brasher, G. Bauman, M. Anthes, E. Bruera, A. Chan, B. Fisher, D. Fulton, S. Gulavita, C. Hao, et al. Abbreviated Course of Radiation Therapy in Older Patients With Glioblastoma Multiforme: A Prospective Randomized Clinical Trial J. Clin. Oncol., May 1, 2004; 22(9): 1583 - 1588. [Abstract] [Full Text] [PDF]